The effect of Trastuzumab treatment on B-cell kinase activities assessed by microarray derived phosphorylation profiles.
Completed
- Conditions
- Breast cancermetastatic breast cancer.10006232
- Registration Number
- NL-OMON30106
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Patients who will be treated with trastuzumab in their best interest as single agent or in combination with chemo- or hormonal therapy (15 patients), or who are about to discontinue treatment with trastuzumab (15 patients for elimination curve), Age >18 years, written informed consent prior to participation in the trial, Able and willing to undergo blood and urine sampling.
Exclusion Criteria
The common exclusion criteria regarding trastuzumab treatment will be followed, and left to the discretion of the treating physician.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary endpoint of this study is to obtain peptide phosphorylation profiles of<br /><br>patients treated with trastuzumab.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints of this study are to correlate the generated<br /><br>phosphorylation profiles as well as metabolic and proteomic changes following<br /><br>trastuzumab treatment to trastuzumab pharmacokinetics .</p><br>